The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 57.00
Bid: 54.00
Ask: 60.00
Change: 1.00 (1.79%)
Spread: 6.00 (11.111%)
Open: 56.00
High: 57.00
Low: 56.00
Prev. Close: 56.00
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

16 Nov 2023 07:00

RNS Number : 6171T
MyCelx Technologies Corporation
16 November 2023
 

The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

16 November 2023

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Trading Update

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company transforming the environmental impact of industry, announces a trading update today.

 

The Company is pleased to announce it has been notified a project valued at $5.4 million to MYCELX has been awarded for deployment of its REGEN media during oil production to meet the strict requirements for overboard discharge. The Company expects a formal purchase order in this regard in the coming days. REGEN was exclusively specified for this project because of its ability to reliably meet the strict water purity requirements of its client and regulations. Whilst the Company will not recognise revenue from the sale of the new equipment and media until 2024, this award will further solidify our position as a leader in clean production technology.

 

Following a robust performance for the first half of 2023, which included a number of project wins and new trials being signed, the Company continues to make progress in all of its target markets. However, unforeseeable events at two projects have impacted H2 2023 revenue. A variable volume dependent contract has not yet met anticipated volumes due to less plant activity. We expect the received volumes to ramp up as plant activity increases. Elsewhere, an unscheduled plant shut down led to the delay in the mobilisation of another project which we now anticipate will commence operations before year-end. As a result, revenue for 2023 is now expected to be in the range of $11.0 million - $11.8 million, against market expectations of $13.1 million. There are several other potential opportunities which could influence year-end revenue within the range, but final outturn is primarily dependent on the activity at these two projects. As a consequence, the Company also expects profitability for 2023 to be reduced versus previous market expectations.

 

Whilst we are disappointed in these unforeseen challenges, these longer duration projects underpin our outlook for next year. These projects together with our advance opportunity pipeline, increasing order book and legacy media sales enable us to increase our 2024 guidance to $17.5 million from market estimates of $14.9 million. The Company will provide further trading updates as we continue to build on the momentum in our core markets.

 

The Company is making progress in the PFAS market continuing with a landfill leachate trial in coordination with a global engineering and consulting company and a series of drinking water trials with a global water treatment company. Whilst we will continue to participate in these and other important trials in 2024, we expect to convert trials to project sales in 2024. Importantly, the U.S. EPA Administrator has recently stated the Agency is committed to finalising PFAS standards for drinking water by year-end 2023 which are expected to reduce the uncertainty that, the Company believes, has contributed to the delay of adoption of new technology and prevented enforcement of PFAS treatment for drinking water.

 

Connie Mixon, CEO, commented:

 

"Although we are revising our financial guidance for 2023, we believe that this is more than offset by the expected increase to revenue in 2024. Following a strong performance in H1 2023 we continue to make consistent progress in all of our core target markets and we are especially pleased by the new contract award for deploying our REGEN media. The Company is poised to capture more projects in this active market where awareness of our REGEN media's capability to support higher production levels and cleaner water is taking hold. We look forward to updating investors on material developments in all of our core markets when we can.

 

As a business, we continue to benefit from our proprietary technology that allows our clients to maximise their operational performance while minimising their environmental impact. These tailwinds leave us well positioned as we head into 2024, as we look to aggressively pursue projects where we have a differentiator, can leverage strategic partnerships and deliver value to our customers and stakeholders."

 

For further information, please contact: 

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nomad and Sole Broker)

Henry Fitzgerald-O'Connor

Gordon Hamilton

 

 

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

Tel: +44 20 7770 6424

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKPBDCBDDFDD
Date   Source Headline
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update
22nd Feb 20247:00 amRNSSaudi Arabia Business Operation Sale
21st Nov 20237:00 amRNSContract Update
16th Nov 20237:00 amRNSTrading Update
26th Sep 20233:10 pmRNSResult of Annual Meeting
20th Sep 20237:00 amRNSHalf Year Results Statement
11th Jul 20237:00 amRNSContract Award
5th Jul 20233:28 pmRNSHolding(s) in Company
3rd Jul 20232:37 pmRNSContract Award & PFAS Update
21st Jun 20237:00 amRNSMailing of AR and Notice of 2023 Annual Meeting
18th May 20237:00 amRNSFinal Results for the Year Ending 31 December 2022
12th May 20237:00 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSuccessful leach testing of PFAS media
14th Mar 20234:50 pmRNSClosure of Restricted Stock Line
8th Mar 20237:00 amRNSPilot Testing Agreement for PFAS Remediation
13th Feb 20237:00 amRNSOperational Update
31st Jan 20237:00 amRNSTrading Update
24th Jan 20237:00 amRNSContract Secured for PFAS Remediation System
8th Dec 20227:00 amRNSTrading Update
27th Sep 20227:00 amRNSHalf Year Results Statement
15th Sep 20227:00 amRNSTrading Update
6th Sep 20222:30 pmRNSHolding(s) in Company
30th Aug 20227:00 amRNSNew Project Awards and Operations Update
13th Jul 20223:32 pmRNSResult of Annual Meeting
13th Jun 20227:00 amRNS2021 Annual Report & Notice of 2022 Annual Meeting
17th May 20227:00 amRNSFinal Results for Year Ending 31 December 2021
3rd May 20227:00 amRNSDirector/PDMR Shareholding
3rd May 20227:00 amRNSChange of Main Office Address
23rd Mar 20229:17 amRNSTR1
21st Mar 20225:56 pmRNSBroker Option
16th Mar 20224:09 pmRNSHolding(s) in Company
11th Mar 20221:10 pmRNSDealings by Directors
11th Mar 20227:00 amRNSProposed Placing and Subscription
11th Feb 20227:00 amRNSTrading Update
2nd Feb 202211:07 amRNSHolding(s) in Company
25th Jan 20227:00 amRNSSuccessful Trial of PFAS Remediation System
10th Jan 20227:00 amRNSAward of Green Economy Mark
23rd Nov 20212:36 pmRNSHolding(s) in Company
11th Nov 202111:51 amRNSDealings by Directors
9th Nov 20214:42 pmRNSDirector/PDMR Shareholding
5th Nov 20217:00 amRNSDirector/PDMR Shareholding
28th Oct 20214:34 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.